Application and Research Progress of Selinexor in Hematologic Tumors Other Than Multiple Myeloma——Review
Exportin-1(XPO1)is a major transporter for hundreds of proteins.Selinexor is the first generation XPO1 inhibitor.At present,selinexor has gained more attention in the application of multiple myeloma(MM).Meanwhile,the latest clinical trials have confirmed that whether it is a single agent or combined with other chemotherapy regimens,selinexor can also achieve good therapeutic effects in patients with leukemia and lymphoma.This review summarizes the results of preclinical studies and clinical trials of selinexor in treatment of non-MM hematological malignancies,aiming to explore how to choose single agent or in combination with other regimens as induction chemotherapy.
NETL
NSTL
万方数据
